![Royston Glasspool](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Royston Glasspool
Direktor/Vorstandsmitglied bei
RELMADA THERAPEUTICS, INC.
Vermögen: - $ am 31.05.2026
Profil
Royston John Glasspool is Chief Executive Officer at VarmX BV since 2024.
Holds director roles at Biotechnology Innovation Organization and Relmada Therapeutics, Inc. since 2019.
Serves as Venture Partner at Agent Capital LLC since 2018.
Former Chief Executive Officer & Director at Anthos Therapeutics, Inc. from 2019 to 2024.
Former Independent Director at DalCor Pharmaceuticals Canada, Inc. from 2017 to 2023.
Former EVP, Head-Corporate Strategy & Customer Operations at Baxalta, Inc. from 2015 to 2017.
Former VP-Emerging Therapies & Market Development at Baxter BioScience Corp.
from 2012 to 2015.
Former Head-Europe Region, Vaccines & Diagnostics at Novartis AG from 2009 to 2012.
Former Director & Vice President at European Vaccine Manufacturers from 2010 to 2012.
Education includes undergraduate degrees from Staffordshire University and Oxford Brookes University, and a graduate degree from Tufts University.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 26.03.2026 | 0 ( -.--% ) | - $ | 31.05.2026 |
Aktive Positionen von Royston Glasspool
| Unternehmen | Position | Beginn |
|---|---|---|
| RELMADA THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 19.12.2019 |
Biotechnology Innovation Organization
 Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Direktor/Vorstandsmitglied | - |
Agent Capital LLC
 Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Private Equity Investor | 01.01.2018 |
Varmx BV
 Varmx BV BiotechnologyHealth Technology Develops and manufactures therapeutic proteins to restore hemostasis | Vorstandsvorsitzender | 01.10.2024 |
Ehemalige bekannte Positionen von Royston Glasspool
| Unternehmen | Position | Ende |
|---|---|---|
Anthos Therapeutics, Inc.
 Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Vorstandsvorsitzender | 22.04.2024 |
DalCor Pharmaceuticals Canada, Inc.
 DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Direktor/Vorstandsmitglied | 01.01.2023 |
| BAXALTA INC | Corporate Officer/Principal | 01.01.2017 |
Baxter BioScience Corp.
 Baxter BioScience Corp. BiotechnologyHealth Technology Provides biopharmaceutical and vaccines services | Corporate Officer/Principal | 01.06.2015 |
European Vaccine Manufacturers | Direktor/Vorstandsmitglied | 01.12.2012 |
Ausbildung von Royston Glasspool
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
66
Beziehungen ersten Grades
13
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 13 |
|---|---|
Biotechnology Innovation Organization
Biotechnology Innovation Organization Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology advocacy organization representing biotech companies, industry leaders and state biotech associations | Commercial Services |
Baxalta, Inc.
 Baxalta, Inc. Pharmaceuticals: MajorHealth Technology Engages in research, development and manufacture of therapies and biopharmaceutical products | Health Technology |
Novartis AG
 Novartis AG Pharmaceuticals: MajorHealth Technology Manufactures and markets health care and nutritional products | Health Technology |
Oxford Brookes University
 Oxford Brookes University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Tufts University
 Tufts University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Staffordshire University
 Staffordshire University Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Baxter BioScience Corp.
Baxter BioScience Corp. BiotechnologyHealth Technology Provides biopharmaceutical and vaccines services | Health Technology |
European Vaccine Manufacturers | |
Relmada Therapeutics, Inc.
 Relmada Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Develops drug products for the treatment of depression and other central nervous system diseases | Health Technology |
DalCor Pharmaceuticals Canada, Inc.
DalCor Pharmaceuticals Canada, Inc. Pharmaceuticals: MajorHealth Technology Develops precision treatments for cardiovascular disease | Health Technology |
Varmx BV
Varmx BV BiotechnologyHealth Technology Develops and manufactures therapeutic proteins to restore hemostasis | Health Technology |
Agent Capital LLC
Agent Capital LLC Investment ManagersFinance Agent Capital invests in companies located in the United States. The firm targets companies operating in the fields of therapeutics sectors and industries. It provides financing for seed, early, late stage, crossover and PIPE stage requirements. The firm acts as a lead investor and also makes co-investments. | Finance |
Anthos Therapeutics, Inc.
Anthos Therapeutics, Inc. BiotechnologyHealth Technology Operates as a clinical-stage biopharmaceutical company that develops therapeutic options for the treatment of cardiovascular metabolic diseases | Health Technology |
